Kinarus Therapeutics Holding AG / Key word(s): Conference/Research Update24-Jun-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.MEDIA RELEASEBasel, Switzerland, 24 June 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory, and ophthalmic disease
BASEL, Switzerland, June 20, 2022--Kinarus has published data showing KIN001’s strong antiviral efficacy against the original SARS-CoV-2 strain and variants of concern (VOC).
Kinarus AG / Key word(s): Merger/MiscellaneousKinarus Therapeutics Announces Name Change and Commences Trading on the SIX Swiss Exchange under ticker “KNRS” 10.06.2022 / 07:00 PDF version Kinarus Therapeutics Holding AG (KNRS) announces its new name and stock symbol, retiring the Perfect Holding (PRFN) name and symbol Kinarus Therapeutics has moved its headquarters to Basel, Switzerland Kinarus AG board of directors and executive management appointed to lead Kinarus Therapeutics Holding AG, comp